MRNS - marinus pharmaceuticals

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
ipo recente, cassa per andare avanti negli studi almeno per altri 2 anni, diretta concorrente di neuren, sembra interessante anche graficamente con la rottura al rialzo di ieri, scambi non eccezionali, la segnalo e proviamo a seguirne gli sviluppi.
Marinus Pharmaceuticals

Pipeline Highlights

Ganaxolone in Adult Focal Onset Epileptic Seizures:

Marinus is currently conducting a Phase 3 clinical trial evaluating ganaxolone in adult patients with drug-resistant focal onset epileptic seizures. Marinus is onboarding four new geographies to double the number of study sites, and plans to enroll up to 300 patients in the United States, Australia, Bulgaria, Germany, Poland and Russia. Data from this Phase 3 study are anticipated in the second half of 2015.

Ganaxolone in Orphan Indications -PCDH19 Female Pediatric Epilepsy and Fragile X Syndrome:

Marinus is preparing to initiate a Phase 2 proof-of-concept, open-label clinical trial in up to ten patients with PCDH19 female pediatric epilepsy. PCDH19 is a rare disorder in which a mutation of the PCDH19 gene causes deficits in GABAergic signaling, which are believed to lead to clusters of seizures that can last from one day to weeks that contribute to developmental delay, intellectual disability and behavioral problems. Although formal epidemiologic data is not available, results from diagnostic screenings indicate that approximately 10% of girls who have seizure onset before five years of age have PCDH19 mutations. Marinus anticipates releasing top-line data from the initial tranche of patients in the first half of 2015.

In addition, enrollment is progressing with the ongoing investigator-sponsored Phase 2 proof-of-concept pediatric clinical trial evaluating ganaxolone as a treatment for behaviors in Fragile X Syndrome (FXS). FXS is a genetic condition that causes intellectual disability, anxiety, and behavioral challenges. Currently, there are no known cures or approved therapies for FXS. Top-line results are anticipated in mid-2015.

Other Formulations of Ganaxolone:

To date, ganaxolone has been administered in over 1,000 patients in oral capsule and suspension dose forms. Marinus is conducting the requisite pre-clinical experiments necessary to ready the intravenous formulation of ganaxolone for human clinical testing. Ganaxolone IV is being developed for the hospital in-patient setting as a compliment to existing oral dose forms for potential use in step-down therapy and for other acute care indications.

Financial Update

Marinus reported net losses of $1.7 million and $7.2 million for the three and nine months ended September 30, 2014, respectively, compared to $1.2 million and $3.9 million for the same periods in the prior year. Cash used in operating activities was $6.6 million for the nine months ended September 30, 2014 compared to $3.5 million for the same period a year ago.

Research and development expenses increased to $1.6 million and $6.5 million for the three and nine months ended September 30, 2014, respectively, compared to $1.0 million and $3.0 million for the same periods in the prior year. The increases resulted primarily from an increase in clinical costs related to our ongoing clinical trial of ganaxolone in patients with focal onset seizures that commenced at the end of 2013. Substantially all research and development expenses relate to our clinical trial in focal onset epileptic seizures.

General and administrative expenses increased to $0.9 million and $1.8 million for the three and nine months ended September 30, 2014, respectively, compared to $0.3 million and $0.9 million for the same periods in the prior year. The increases in general and administrative expenses were primarily due to the hiring of new management and the upward scaling of our operations in connection with both our new public company status and ongoing clinical trial of ganaxolone in patients with focal onset seizures that commenced during 2013.

At September 30, 2014, the Company had cash and cash equivalents of $47.1 million, compared to $10.0 million at December 31, 2013. The increase was primarily due to $41.2 million in net proceeds received from the sale of 5,758,000 shares of common stock through the initial public offering that the Company completed during the third quarter. The Company believes that its cash and cash equivalents as of September 30, 2014 is adequate to fund operations into 2016.
 

Allegati

  • marinus pipeline.png
    marinus pipeline.png
    90 KB · Visite: 725
  • mrns.png
    mrns.png
    65,9 KB · Visite: 713
la segnalazione non era malaccio, solo un +100 peccato che scambiava poco e non sono entrato :(
 

Allegati

  • mrns.png
    mrns.png
    19,2 KB · Visite: 635
Mitico! Ps: seguo sempre con interesse i tuoi post ;)
 
da seguire occhio in apertura.
 

Allegati

  • sc.png
    sc.png
    24,2 KB · Visite: 588
...non potevo non farti compagnia...sono dentro a 1,30 tondi...piace pure a me :D
 
ma questo è veramente celebroleso....non ho mai visto un mentecatto più ciordo di questo...
 
tosta la res. a 1,39 :wall: ma anche le mura di gerico caddero:D
 

Allegati

  • sc.png
    sc.png
    24,4 KB · Visite: 236
primo obiettivo a 1,58 raggiunto,il prossimo è a !;)= circa.
 

Allegati

  • sc.png
    sc.png
    18,5 KB · Visite: 215
vabbuò ma a noi
 

Allegati

  • 3m0ur7.jpg
    3m0ur7.jpg
    41,9 KB · Visite: 214
nei forum USA dicono che la società potrebbe esser presto acquistata da una big

ma io non capisco......


ma perchè ogni cosa che dicono sui forum americani voi ci credete:wall::wall::angry:


è un forum!!

anche su finanzaonline c'è un tizio bruciato che dice che XGTI va a 10$ ed è solo scesa da quando lo dice!!!:wall:

che nervi...
 
sui forum americani dicono che tra poco venderanno l'aria...comprate l'aria!!!!
 
Indietro